News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Labtec GmbH's Sufentanil Patch for Chronic Pain Enters Phase II in Cooperation With Hameln Pharmaceuticals gmbh


11/1/2010 10:59:18 AM

LANGENFELD/RHEINLAND, Germany--(BUSINESS WIRE)--Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES